LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Pfizer

Cerrado

SectorSanidad

22.97 0.88

Resumen

Variación precio

24h

Actual

Mínimo

22.51

Máximo

23.08

Métricas clave

By Trading Economics

Ingresos

2.6B

3B

Ventas

-4B

14B

P/B

Media del Sector

16.872

54.379

BPA

0.92

Rentabilidad por dividendo

7.23

Margen de beneficios

21.633

Empleados

81,000

EBITDA

2B

4.5B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+21.5% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

7.23%

2.55%

Próximas Ganancias

29 jul 2025

Fecha Próximo Dividendo

13 jun 2025

Próxima Fecha de Ex Dividendo

9 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-16B

135B

Apertura anterior

22.09

Cierre anterior

22.97

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

144 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Pfizer Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 may 2025, 18:41 UTC

Principales Movimientos del Mercado

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 abr 2025, 11:24 UTC

Ganancias

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

7 may 2025, 17:01 UTC

Principales Noticias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 may 2025, 09:30 UTC

Principales Noticias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 may 2025, 15:13 UTC

Charlas de Mercado
Ganancias

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 may 2025, 14:07 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 11:58 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 11:06 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 10:48 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 abr 2025, 19:47 UTC

Ganancias

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 abr 2025, 18:11 UTC

Ganancias

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 abr 2025, 15:22 UTC

Ganancias

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 abr 2025, 12:03 UTC

Adquisiciones, fusiones, absorciones

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 abr 2025, 11:46 UTC

Ganancias

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 abr 2025, 11:42 UTC

Ganancias

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 abr 2025, 11:12 UTC

Ganancias

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 abr 2025, 10:52 UTC

Ganancias

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 abr 2025, 10:51 UTC

Ganancias

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 abr 2025, 10:50 UTC

Ganancias

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 abr 2025, 10:47 UTC

Ganancias

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 abr 2025, 10:47 UTC

Ganancias

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 abr 2025, 10:46 UTC

Ganancias

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 abr 2025, 10:45 UTC

Ganancias

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29 abr 2025, 10:45 UTC

Ganancias

Pfizer 1Q EPS 52c >PFE

29 abr 2025, 10:45 UTC

Ganancias

Pfizer 1Q Adj EPS 92c >PFE

29 abr 2025, 10:45 UTC

Ganancias

Pfizer 1Q Net $2.97B >PFE

29 abr 2025, 10:45 UTC

Ganancias

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

29 abr 2025, 10:45 UTC

Ganancias

Pfizer Sees FY Rev $61B-$64B >PFE

29 abr 2025, 10:45 UTC

Ganancias

Pfizer 1Q Rev $13.7B >PFE

29 abr 2025, 09:20 UTC

Ganancias
Acciones populares

Stocks to Watch Tuesday: GM, Porsche, Coca-Cola -- WSJ

Comparación entre iguales

Cambio de precio

Pfizer previsión

Precio Objetivo

By TipRanks

21.5% repunte

Estimación a 12 Meses

Media 27.69 USD  21.5%

Máximo 32 USD

Mínimo 23 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pfizer Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

5

Comprar

13

Mantener

0

Vender

Puntuación técnica

By Trading Central

22.475 / 22.855Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

144 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.